Press releases

19 November, 2015

Regulatory

NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study

Lund, Sweden, 19 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed the continuation of the on-going P ...

18 November, 2015

Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015

Focus forward on R&D

2 November, 2015

Regulatory

NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress

Lund, Sweden, 2 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the presentation of preclinical data from its Complex I deficiency discovery program a ...

28 October, 2015

Regulatory

NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus

Lund, Sweden, 28 October 2015- NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the ...

23 October, 2015

Regulatory

NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer

Lund, Sweden, 23 October 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 ...

16 October, 2015

Regulatory

Annual General Meeting 2016 and Nomination Committee

The Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 28 April 2016 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.

1 September, 2015

Regulatory

NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company. Effective today, Mikael Brönnegård will no longer serve as Chief Executive Off ...

31 August, 2015

Regulatory

NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...

19 August, 2015

Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015

Negative top-line result of phase III study and continued progress in other clinical projects

26 June, 2015

Regulatory

NeuroVive share upgraded on OTC market in US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade ...

1 June, 2015

Regulatory

NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...

29 May, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...